Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.